166 related articles for article (PubMed ID: 17879406)
1. Type 2 diabetes mellitus and CA 19-9 levels.
Uygur-Bayramicli O; Dabak R; Orbay E; Dolapcioglu C; Sargin M; Kilicoglu G; Guleryuzlu Y; Mayadagli A
World J Gastroenterol; 2007 Oct; 13(40):5357-9. PubMed ID: 17879406
[TBL] [Abstract][Full Text] [Related]
2. Serum CA 19-9 Level is Correlated to the Clinical Characteristics and Chronic Complications of Patients Newly Diagnosed with Type 2 Diabetes Mellitus.
Cui L; Lv N; Li B; Tao J; Zheng X; Yan Y; Liu C
Exp Clin Endocrinol Diabetes; 2021 Aug; 129(8):581-586. PubMed ID: 31461764
[TBL] [Abstract][Full Text] [Related]
3. Effect of glycotoxicity and lipotoxicity on carbohydrate antigen 19 - 9 in the patients with diabetes.
Liu XY; Wang XH
BMC Endocr Disord; 2024 Apr; 24(1):51. PubMed ID: 38654232
[TBL] [Abstract][Full Text] [Related]
4. Proposed cut-off value of CA19-9 for detecting pancreatic cancer in patients with diabetes: a case-control study.
Murakami M; Nagai Y; Tenjin A; Tanaka Y
Endocr J; 2018 Jun; 65(6):639-643. PubMed ID: 29643268
[TBL] [Abstract][Full Text] [Related]
5. New-onset type 2 diabetes mellitus--A high-risk group suitable for the screening of pancreatic cancer?
Illés D; Terzin V; Holzinger G; Kosár K; Róka R; Zsóri G; Ábrahám G; Czakó L
Pancreatology; 2016; 16(2):266-71. PubMed ID: 26777407
[TBL] [Abstract][Full Text] [Related]
6. CA 72-4 levels in patients with type 2 diabetes mellitus.
Demirci H; Erdamar H; Karakoc A; Akturk M; Yilmaz M; Arslan M
Int J Clin Pract; 2010 Jan; 64(1):34-8. PubMed ID: 18205795
[TBL] [Abstract][Full Text] [Related]
7. The Influence of Metformin on Serum Carbohydrate Antigen 19-9 (CA 19-9) Levels in Type 2 Diabetes Mellitus Patients.
Ankit BS; Agrawal R; Gadhwal A; Chahar C; Agrawal RP
J Assoc Physicians India; 2018 Mar; 66(3):38-41. PubMed ID: 30341867
[TBL] [Abstract][Full Text] [Related]
8. Clinical implication of elevated CA 19-9 level and the relationship with glucose control state in patients with type 2 diabetes.
Kim SH; Baek CO; Lee KA; Park TS; Baek HS; Jin HY
Endocrine; 2014 Jun; 46(2):249-55. PubMed ID: 24114405
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic cancer biomarkers discovery by surface-enhanced laser desorption and ionization time-of-flight mass spectrometry.
Navaglia F; Fogar P; Basso D; Greco E; Padoan A; Tonidandel L; Fadi E; Zambon CF; Bozzato D; Moz S; Seraglia R; Pedrazzoli S; Plebani M
Clin Chem Lab Med; 2009; 47(6):713-23. PubMed ID: 19426140
[TBL] [Abstract][Full Text] [Related]
10. Elevated tumor-associated antigen CA 19-9 in a patient with an enlarged pancreas: does it always imply malignancy?
Tolliver BA; O'Brien BL
South Med J; 1997 Jan; 90(1):89-90. PubMed ID: 9003836
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of exocrine pancreatic insufficiency in type 2 diabetes mellitus with poor glycemic control.
Terzin V; Várkonyi T; Szabolcs A; Lengyel C; Takács T; Zsóri G; Stájer A; Palkó A; Wittmann T; Pálinkás A; Czakó L
Pancreatology; 2014; 14(5):356-60. PubMed ID: 25278304
[TBL] [Abstract][Full Text] [Related]
12. Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging.
Nitta Y; Tahara N; Tahara A; Honda A; Kodama N; Mizoguchi M; Kaida H; Ishibashi M; Hayabuchi N; Ikeda H; Yamagishi S; Imaizumi T
JACC Cardiovasc Imaging; 2013 Nov; 6(11):1172-82. PubMed ID: 24229770
[TBL] [Abstract][Full Text] [Related]
13. Poorly Regulated Blood Glucose in Diabetic Patients-predictor of Acute Infections.
Burekovic A; Dizdarevic-Bostandzic A; Godinjak A
Med Arch; 2014 Jun; 68(3):163-6. PubMed ID: 25568525
[TBL] [Abstract][Full Text] [Related]
14. Lymphoepithelial cysts of the pancreas. Can preoperative imaging distinguish this benign lesion from malignant or pre-malignant cystic pancreatic lesions?
Kavuturu S; Sarwani NE; Ruggeiro FM; Deshaies I; Kimchi ET; Kaifi JT; Staveley-O'Carroll KF; Gusani NJ
JOP; 2013 May; 14(3):250-5. PubMed ID: 23669473
[TBL] [Abstract][Full Text] [Related]
15. Glycated haemoglobin and glycaemic control of diabetics in Ilorin.
Adebisi SA; Oghagbon EK; Akande TM; Olarinoye JK
Niger J Clin Pract; 2009 Mar; 12(1):87-91. PubMed ID: 19562929
[TBL] [Abstract][Full Text] [Related]
16. CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease.
Morris-Stiff G; Teli M; Jardine N; Puntis MC
Hepatobiliary Pancreat Dis Int; 2009 Dec; 8(6):620-6. PubMed ID: 20007080
[TBL] [Abstract][Full Text] [Related]
17. Elevated levels of CA 19-9 and CEA in pancreatic cancer-associated diabetes.
Guo Q; Kang M; Zhang B; Chen Y; Dong X; Wu Y
J Cancer Res Clin Oncol; 2010 Nov; 136(11):1627-31. PubMed ID: 20174821
[TBL] [Abstract][Full Text] [Related]
18. Adjusting CA19-9 values to predict malignancy in obstructive jaundice: influence of bilirubin and C-reactive protein.
La Greca G; Sofia M; Lombardo R; Latteri S; Ricotta A; Puleo S; Russello D
World J Gastroenterol; 2012 Aug; 18(31):4150-5. PubMed ID: 22919247
[TBL] [Abstract][Full Text] [Related]
19. Predictors of malignancy in pancreatic head mass: a prospective study.
Sivaraman A; Muthukrishnan A; Boopathy Senguttvan N; Anil Suchak S; Kannan U
Pan Afr Med J; 2011; 9():30. PubMed ID: 22145063
[TBL] [Abstract][Full Text] [Related]
20. Prognostic relevance of preoperative diabetes mellitus and the degree of hyperglycemia on the outcomes of resected pancreatic ductal adenocarcinoma.
Lee W; Yoon YS; Han HS; Cho JY; Choi Y; Jang JY; Choi H
J Surg Oncol; 2016 Feb; 113(2):203-8. PubMed ID: 26799261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
